Literature DB >> 9876321

Insulin signalling in heart involves insulin receptor substrates-1 and -2, activation of phosphatidylinositol 3-kinase and the JAK 2-growth related pathway.

L A Velloso1, C R Carvalho, F A Rojas, F Folli, M J Saad.   

Abstract

OBJECTIVE: Hyperinsulinemia is a common feature of obesity and hypertension and may be associated with abnormal metabolism and growth of heart muscle and vascular wall. Most of the known actions of insulin were characterised in muscle, adipose tissue and liver. In this study we investigate the initial steps of insulin signalling in rat heart.
METHODS: After insulin infusion in the cava vein of male Wistar rats, the insulin receptor, insulin receptor substrates-1 and -2, phosphatidylinositol 3-kinase activity and Janus kinase (JAK) 2 engagement were studied by immunoprecipitation and immunoblot of heart extracts.
RESULTS: An insulin load induces rapid autophosphorylation of the insulin receptor which is followed by the phosphorylation of insulin receptor substrates-1 and -2. The phosphorylation of these early intracellular substrates leads to the association of the p85 subunit of phosphatidylinositol 3-kinase and subsequent activation of its catalytic p110 subunit. Besides activation of the lipid metabolising enzyme phosphatidylinositol 3-kinase, the phosphorylation of insulin receptor substrates-1 and -2 engages the intracellular kinase JAK 2 and induces JAK 2-STAT 1 complex formation.
CONCLUSIONS: We demonstrate that the early steps of insulin signalling in heart include the phosphorylation-activation of the insulin receptor, engagement of insulin receptor substrates-1 and -2 with the consequent activation of phosphatidylinositol 3-kinase and the involvement of the recently discovered growth related pathway--JAK 2-STAT 1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9876321     DOI: 10.1016/s0008-6363(98)00098-4

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  9 in total

1.  Regulation of heart insulin receptor tyrosine kinase activity by magnesium and spermine.

Authors:  Ralph Paxton; Lingxiang Ye
Journal:  Mol Cell Biochem       Date:  2005-09       Impact factor: 3.396

Review 2.  The JAK/STAT signaling pathway: from bench to clinic.

Authors:  Xiaoyi Hu; Jing Li; Maorong Fu; Xia Zhao; Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2021-11-26

3.  Skeletal muscle growth in young rats is inhibited by chronic exposure to IL-6 but preserved by concurrent voluntary endurance exercise.

Authors:  P W Bodell; E Kodesh; F Haddad; F P Zaldivar; D M Cooper; G R Adams
Journal:  J Appl Physiol (1985)       Date:  2008-12-04

Review 4.  JAK redux: a second look at the regulation and role of JAKs in the heart.

Authors:  Mazen Kurdi; George W Booz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

5.  JAK-STAT: Getting to the heart of the matter.

Authors:  Sean P Barry
Journal:  JAKSTAT       Date:  2012-04-01

6.  Molecular basis of signaling specificity of insulin and IGF receptors: neglected corners and recent advances.

Authors:  Kenneth Siddle
Journal:  Front Endocrinol (Lausanne)       Date:  2012-02-28       Impact factor: 5.555

7.  Insulin Resistance and Pellino-1 Mediated Decrease in the Activities of Vasodilator Signaling Contributes to Sunitinib-Induced Hypertension.

Authors:  Yang Liu; Liang-Liang Tang; Chen Liang; Ming-Ming Wu; Zhi-Ren Zhang
Journal:  Front Pharmacol       Date:  2021-03-25       Impact factor: 5.810

Review 8.  Insulin Receptors and Insulin Action in the Heart: The Effects of Left Ventricular Assist Devices.

Authors:  Konstantina Pantazi; Eleni Karlafti; Alexandra Bekiaridou; Matthaios Didagelos; Antonios Ziakas; Triantafyllos Didangelos
Journal:  Biomolecules       Date:  2022-04-14

Review 9.  "Do We Know Jack" About JAK? A Closer Look at JAK/STAT Signaling Pathway.

Authors:  Emira Bousoik; Hamidreza Montazeri Aliabadi
Journal:  Front Oncol       Date:  2018-07-31       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.